GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
A

Arrowhead Pharmaceuticals ARWR · USD

Health Care · US listing · 🇺🇸 United States

Compare

49.24

-15.34%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2025

Revenue

$829.4m

FY2016FY2025

Net income

−$1.6m

FY2016FY2025

Free cash flow

$156.9m

FY2016FY2025

Shareholders' equity

$466.1m

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue$829.4m$3.6m$240.7m$243.2m$138.3m$88.0m$168.8m$16.1m$31.4m$158,333
Gross profit$829.4m−$15.0m$228.2m$243.2m$138.3m$88.0m$168.8m$16.1m$31.4m$158,333
Research and development$607.2m$489.2m$342.3m$297.3m$199.0m$123.5m$76.6m$48.3m$46.3m$41.5m
Operating income$98.3m−$602.8m−$203.5m−$178.5m−$149.0m−$93.2m$61.2m−$55.9m−$37.0m−$81.7m
Net income−$1.6m−$599.5m−$205.3m−$176.5m−$140.8m−$84.6m$68.0m−$54.5m−$34.4m−$81.7m
Diluted earnings per share-0.01-4.80-1.91-1.66-1.35-0.820.70-0.57-0.46-1.14

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assets$1.39bn$1.14bn$765.6m$691.9m$710.1m$522.5m$349.8m$111.6m$104.0m$128.2m
Cash and short-term investments$919.4m$681.0m$403.6m$376.4m$367.8m$315.5m$258.7m$76.5m$65.6m$85.4m
Total liabilities$881.9m$948.7m$478.4m$273.6m$301.3m$60.7m$105.8m$16.4m$23.2m$33.2m
Debt$622.3m$734.5m—————$2.3m$2.5m$2.7m
Shareholders' equity$466.1m$185.4m$271.3m$398.5m$408.8m$461.8m$244.6m$95.8m$81.4m$95.6m
Shares outstanding141m125m107m106m105m103m97m96m75m71m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations$179.6m−$462.9m−$153.9m−$136.1m$171.3m−$95.8m$173.0m−$47.2m−$23.9m−$64.4m
Capital spending−$22.7m−$141.5m−$176.7m−$52.8m−$23.6m−$12.0m−$12.0m−$1.4m−$7.9m−$3.9m
Free cash flow$156.9m−$604.3m−$330.6m−$188.9m$147.7m−$107.8m$161.0m−$48.6m−$31.9m−$68.3m

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue$75.3m$73.7m$264.0m$256.5m$27.8m$542.7m$2.5m$23.6m
Gross profit$75.3m$73.7m$264.0m$256.5m$27.8m$542.7m$2.5m−$5.0m
Operating income−$171.3m−$141.3m$40.8m$44.1m−$165.7m$381.2m−$161.1m−$165.3m
Net income−$194.3m−$132.7m$30.8m−$23.8m−$175.2m$370.4m−$173.1m−$170.5m
Diluted earnings per share-1.36-0.930.22-0.17-1.252.63-1.39-1.37
Cash from operations−$177.0m$84.0m$13.0m$20.0m−$154.0m$460.0m−$146.0m−$137.0m
Capital spending−$3.0m−$2.0m−$2.0m−$7.0m−$2.0m−$5.0m−$7.0m−$24.0m
Free cash flow−$180.0m$82.0m$11.0m$13.0m−$156.0m$455.0m−$153.0m−$161.0m
Total assets$2.11bn$2.27bn$1.60bn$1.39bn$1.38bn$1.57bn$1.01bn$1.14bn
Cash and short-term investments$1.60bn$1.78bn$916.6m$919.4m$900.4m$1.10bn$552.9m$681.0m
Debt$864.1m$889.4m$210.6m$262.2m$247.3m$280.7m$416.0m$399.5m
Shareholders' equity$465.5m$614.0m$568.4m$466.1m$522.3m$683.3m$52.6m$185.4m

Financial ratios

Data as of 7 Oct 2026

FY2025FY2024FY2023FY2022FY2021FY2020
Gross margin100.0%-423.7%94.8%100.0%100.0%100.0%
Operating margin17.0%-16336.5%-78.2%-73.4%-101.9%-105.9%
Net margin-0.2%-16882.4%-85.3%-72.6%-101.9%-96.1%
Return on equity-0.3%-323.3%-75.7%-44.3%-34.5%-18.3%
Return on assets-0.1%-52.6%-26.8%-25.5%-19.8%-16.2%
Free cash flow yield2.3%-4.2%0.3%-1.3%3.0%-1.3%
Revenue growth23258.2%-98.5%-1.0%75.9%57.2%-47.9%
Earnings growth-99.7%192.0%16.3%25.3%66.6%-224.4%
Current ratio4.86x6.74x3.98x2.92x2.62x7.92x
Debt to equity0.56x2.15x0.04x0.01x0.01x0.00x
Equity ratio33.6%16.3%35.4%57.6%57.6%88.4%
Interest coverage1.58x-17.93x-10.27x-35.47x-23.01x-0.01x
R&D as a share of sales73.2%13776.9%142.2%122.2%149.2%140.4%
Buybacks as a share of market value-12.7%-16.2%-1.3%-1.4%-1.7%-5.8%

Growth per year

Compound annual rate

3 years5 years10 years
Revenue50.5%56.6%115.6%
Net income-79.0%-54.6%-33.2%

Average margins

Over each period

1 year3 years5 years10 years
Gross margin97.8%97.6%98.0%98.2%
Operating margin-60.6%-67.3%-73.1%-76.0%
Net margin-72.2%-74.6%-78.3%-79.7%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings-5727.4-3.9-16.0-24.4-49.2-93.390.6-21.8-8.0-1.4
Price to sales11.3—13.717.750.189.636.573.58.8—

Market value over time

31 Aug 2016 to 6 Oct 2026, in USD

$415.8m$8.82bn

Share price return

Finished calendar years

2025202420232022202120202019201820172016
Return226%-32%-3%-56%-14%29%393%275%177%-37%

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years.

  • 10-to-1 reverse split · 17 Nov 2011
  • 65-to-1 reverse split · 15 Jan 2004

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.